Choosing Among Common Data Models for Real‐World Data Analyses Fit for Making Decisions About the Effectiveness of Medical Products

Many real‐world data analyses use common data models (CDMs) to standardize terminologies for medication use, medical events and procedures, data structures, and interpretations of data to facilitate analyses across data sources. For decision makers, key aspects that influence the choice of a CDM may include (i) adaptability to a specific question; (ii) transparency to reproduce findings, assess validity, and instill confidence in findings; and (iii) ease and speed of use. Organizing CDMs preserve the original information from a data source and have maximum adaptability. Full mapping data models, or preconfigured rules systems, are easy to use, since all raw codes are mapped to medical constructs. Adaptive rule systems grow libraries of reusable measures that can easily adjust to preserve adaptability, expedite analyses, and ensure study‐specific transparency.

[1]  W Katherine Yih,et al.  Active Surveillance for Adverse Events: The Experience of the Vaccine Safety Datalink Project , 2011, Pediatrics.

[2]  Kenneth D. Mandl,et al.  Data interchange using i2b2 , 2016, J. Am. Medical Informatics Assoc..

[3]  D. Madigan,et al.  Evaluating the impact of database heterogeneity on observational study results. , 2013, American journal of epidemiology.

[4]  M. Reichman,et al.  Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study , 2017, Diabetes Care.

[5]  Richard Platt,et al.  Four health data networks illustrate the potential for a shared national multipurpose big-data network. , 2014, Health affairs.

[6]  S. Schneeweiss,et al.  Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. , 2017, The New England journal of medicine.

[7]  J. Rassen,et al.  Prospective Cohort Studies of Newly Marketed Medications: Using Covariate Data to Inform the Design of Large-Scale Studies , 2014, Epidemiology.

[8]  L. Lix,et al.  Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study , 2017, British Medical Journal.

[9]  J. Avorn,et al.  A review of uses of health care utilization databases for epidemiologic research on therapeutics. , 2005, Journal of clinical epidemiology.

[10]  P. Ryan,et al.  Fidelity Assessment of a Clinical Practice Research Datalink Conversion to the OMOP Common Data Model , 2014, Drug Safety.

[11]  G. Requena,et al.  Understanding inconsistency in the results from observational pharmacoepidemiological studies: the case of antidepressant use and risk of hip/femur fractures , 2016, Pharmacoepidemiology and drug safety.

[12]  R. Califf,et al.  Real-World Evidence - What Is It and What Can It Tell Us? , 2016, The New England journal of medicine.

[13]  David Madigan,et al.  Empirical Performance of a New User Cohort Method: Lessons for Developing a Risk Identification and Analysis System , 2013, Drug Safety.

[14]  A. Bate,et al.  Evidence generation from healthcare databases: recommendations for managing change , 2016, Pharmacoepidemiology and drug safety.

[15]  鮫島 浩,et al.  Population-based study からみた神経予後不良因子の検討 , 2009 .

[16]  Robert W. Platt,et al.  How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias , 2020, Pharmacoepidemiology and drug safety.

[17]  Andrew Bate,et al.  An Evaluation of the THIN Database in the OMOP Common Data Model for Active Drug Safety Surveillance , 2013, Drug Safety.

[18]  Sebastian Schneeweiss,et al.  Use of Health Care Databases to Support Supplemental Indications of Approved Medications , 2018, JAMA internal medicine.

[19]  M E Matheny,et al.  Creating a Common Data Model for Comparative Effectiveness with the Observational Medical Outcomes Partnership , 2015, Applied Clinical Informatics.

[20]  Andrew Bate,et al.  A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance , 2015, Drug Safety.

[21]  Kevin Haynes,et al.  Electronic clinical laboratory test results data tables: lessons from Mini‐Sentinel , 2014, Pharmacoepidemiology and drug safety.

[22]  James R. Rogers,et al.  Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi‐Database Cohort Study , 2017, Arthritis & rheumatology.

[23]  M. Reichman,et al.  Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs , 2016, Annals of Internal Medicine.

[24]  Characteristics of study design and elements that may contribute to the success of electronic safety monitoring systems , 2014, Pharmacoepidemiology and drug safety.

[25]  S. Schneeweiss,et al.  Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study , 2018, British Medical Journal.

[26]  J. Avorn,et al.  Agreement between drug treatment data and a discharge diagnosis of diabetes mellitus in the elderly. , 1999, American journal of epidemiology.

[27]  J M Robins,et al.  Confounding and misclassification. , 1985, American journal of epidemiology.

[28]  D. Malone,et al.  Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies? , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[29]  L. Smeeth,et al.  Risk of acute liver injury associated with use of antibiotics. Comparative cohort and nested case–control studies using two primary care databases in Europe , 2016, Pharmacoepidemiology and drug safety.

[30]  J. Gagne,et al.  Prospective surveillance pilot of rivaroxaban safety within the US Food and Drug Administration Sentinel System , 2018, Pharmacoepidemiology and drug safety.

[31]  Marsha A Raebel,et al.  Design considerations, architecture, and use of the Mini‐Sentinel distributed data system , 2012, Pharmacoepidemiology and drug safety.

[32]  C. Vogeli,et al.  Primary Medication Non-Adherence: Analysis of 195,930 Electronic Prescriptions , 2010, Journal of General Internal Medicine.

[33]  J. Lei,et al.  Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how? , 2014, Journal of internal medicine.

[34]  Werner Ceusters,et al.  A Realism-Based View on Counts in OMOP's Common Data Model , 2017, pHealth.

[35]  Dennis Andersson,et al.  A retrospective cohort study , 2018 .

[36]  Jeremy A. Rassen,et al.  Transparency and reproducibility of published observational cohort studies , 2015 .

[37]  M. Schuemie,et al.  Combining electronic healthcare databases in Europe to allow for large‐scale drug safety monitoring: the EU‐ADR Project , 2011, Pharmacoepidemiology and drug safety.

[38]  JA Rassen,et al.  Transparency and Reproducibility of Observational Cohort Studies Using Large Healthcare Databases. , 2016, Clinical pharmacology and therapeutics.

[39]  R Platt,et al.  Real World Data in Adaptive Biomedical Innovation: A Framework for Generating Evidence Fit for Decision‐Making , 2016, Clinical pharmacology and therapeutics.

[40]  Roy Pardee,et al.  The National Patient-Centered Clinical Research Network (PCORnet) Bariatric Study Cohort: Rationale, Methods, and Baseline Characteristics , 2017, JMIR research protocols.

[41]  Peter R. Rijnbeek,et al.  Converting to a Common Data Model: What is Lost in Translation? , 2014, Drug Safety.

[42]  Marius Fieschi,et al.  Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project , 2013, J. Am. Medical Informatics Assoc..

[43]  Guilherme Del Fiol,et al.  Evaluating common data models for use with a longitudinal community registry , 2016, J. Biomed. Informatics.

[44]  Edoardo Vacchi,et al.  Data Extraction and Management in Networks of Observational Health Care Databases for Scientific Research: A Comparison of EU-ADR, OMOP, Mini-Sentinel and MATRICE Strategies , 2016, EGEMS.

[45]  Marsha E Reichman,et al.  Dabigatran and postmarketing reports of bleeding. , 2013, The New England journal of medicine.

[46]  Griffin M. Weber,et al.  Serving the enterprise and beyond with informatics for integrating biology and the bedside (i2b2) , 2010, J. Am. Medical Informatics Assoc..

[47]  Sengwee Toh,et al.  Design and analysis choices for safety surveillance evaluations need to be tuned to the specifics of the hypothesized drug–outcome association , 2016, Pharmacoepidemiology and drug safety.

[48]  Adrian F Hernandez,et al.  Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. , 2012, Archives of internal medicine.

[49]  Olaf Klungel,et al.  Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[50]  David Madigan,et al.  Good practices for real‐world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR‐ISPE Special Task Force on real‐world evidence in health care decision making , 2017, Pharmacoepidemiology and drug safety.

[51]  Sebastian Schneeweiss,et al.  A basic study design for expedited safety signal evaluation based on electronic healthcare data , 2010, Pharmacoepidemiology and drug safety.

[52]  S Toh,et al.  Successful Comparison of US Food and Drug Administration Sentinel Analysis Tools to Traditional Approaches in Quantifying a Known Drug‐Adverse Event Association , 2016, Clinical pharmacology and therapeutics.

[53]  Lisa M. LaVange,et al.  Multidimensional Evidence Generation and FDA Regulatory Decision Making: Defining and Using "Real-World" Data. , 2017, JAMA.